← Back to Search

Artificial Tears

Systane Complete PF (Treatment) for Dry Eye Syndrome (AlconAT Trial)

Phase 4
Waitlist Available
Led By Meng C. Lin, OD, PhD
Research Sponsored by University of California, Berkeley
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up deq-5 questionnaire administered once at post-run-in baseline and once at 3mo follow-up visit
Awards & highlights

AlconAT Trial Summary

This trial will compare the effects of 3 lipid-based artificial tears and a non-lipid one on tear film structure, stability, and symptoms of dry eye disease.

Eligible Conditions
  • Dry Eye Syndrome

AlconAT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~deq-5 questionnaire administered once at post-run-in baseline and once at 3mo follow-up visit
This trial's timeline: 3 weeks for screening, Varies for treatment, and deq-5 questionnaire administered once at post-run-in baseline and once at 3mo follow-up visit for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Tear Lipid Layer Thickness
Secondary outcome measures
Tear Film Thinning Rate
Tear Lipid Layer Uniformity
Other outcome measures
Exploratory - Subjective Symptoms - DEQ-5
Exploratory - Subjective Symptoms - OSDI
Exploratory - Subjective Symptoms - SANDE

AlconAT Trial Design

4Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Systane Complete PF (Treatment)Experimental Treatment1 Intervention
Masked subjects assigned to Arm 1 will use Systane Complete PF artificial tear drops 4 times per day (QID) to treat dry eye symptoms over a 3 month period.
Group II: CVS Health Lubricant Eye Drop (PG 0.6%) (Active Comparator 2)Active Control1 Intervention
Masked subjects assigned to Arm 4 will use CVS Health Lubricant Eye Drop (PG 0.6%) artificial tear drops 4 times per day (QID) to treat dry eye symptoms over a 3 month period.
Group III: Refresh Optive Mega-3 PF (Active Comparator 1)Active Control1 Intervention
Masked subjects assigned to Arm 3 will use Refresh Optive Mega-3 PF artificial tear drops 4 times per day (QID) to treat dry eye symptoms over a 3 month period.
Group IV: Refresh Relieva PF (Control)Placebo Group1 Intervention
Masked subjects assigned to Arm 2 will use Refresh Relieva PF artificial tear drops 4 times per day (QID) to treat dry eye symptoms over a 3 month period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Systane Complete PF
2023
Completed Phase 4
~90

Find a Location

Who is running the clinical trial?

University of California, BerkeleyLead Sponsor
180 Previous Clinical Trials
721,102 Total Patients Enrolled
Alcon ResearchIndustry Sponsor
703 Previous Clinical Trials
124,387 Total Patients Enrolled
Meng C. Lin, OD, PhDPrincipal InvestigatorUniversity of California Berkeley Clinical Research Center
1 Previous Clinical Trials
95 Total Patients Enrolled

Media Library

CVS Health Lubricant Eye Drop (PG 0.6%) (Artificial Tears) Clinical Trial Eligibility Overview. Trial Name: NCT05705518 — Phase 4
Dry Eye Syndrome Research Study Groups: Systane Complete PF (Treatment), Refresh Relieva PF (Control), CVS Health Lubricant Eye Drop (PG 0.6%) (Active Comparator 2), Refresh Optive Mega-3 PF (Active Comparator 1)
Dry Eye Syndrome Clinical Trial 2023: CVS Health Lubricant Eye Drop (PG 0.6%) Highlights & Side Effects. Trial Name: NCT05705518 — Phase 4
CVS Health Lubricant Eye Drop (PG 0.6%) (Artificial Tears) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05705518 — Phase 4
Dry Eye Syndrome Patient Testimony for trial: Trial Name: NCT05705518 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can Systane Complete PF be administered without risk to the patient?

"Systane Complete PF (Treatment) has been approved by the relevant regulatory bodies, making its safety score a 3 on our scale of 1 to 3."

Answered by AI

Are new participants invited to join this clinical trial?

"The clinical trial, which was initially listed on 30th January 2023 and last edited on 20th January 2023 no longer accepts new participants. However, 78 other studies are actively in search of enrolment at this time."

Answered by AI

Who else is applying?

What state do they live in?
Texas
California
What site did they apply to?
Clinical Research Center, School of Optometry, University of California, Berkeley
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

I'd like to find help for my dry eyes.
PatientReceived no prior treatments

What questions have other patients asked about this trial?

Do you cover travel?
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
Artificial Tears, Tear Lipids and Tear Film Dynamics
2023. "Artificial Tears, Tear Lipids and Tear Film Dynamics". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05705518.
~39 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top